Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy?

Histopathology

Volumn 59, Issue 4, 2011, Pages 650-659

  Park, Seog Yun ^a   Chang, Hee Jin ^a   Kim, Dae Yong ^a   Jung, Kyung Hae ^b   Kim, Sun Young ^a   Park, Ji Won ^a   Oh, Jae Hwan ^a   Lim, Seok Byung ^b   Choi, Hyo Seong ^a   Jeong, Seung Yong ^c  

^a National Cancer Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Colorectal cancer; Preoperative chemoradiotherapy; Regression grade; Step section; Survival

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MUCIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER SURGERY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT RESPONSE; TUMOR CELL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; FEMALE; HISTOLOGICAL TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PATHOLOGY, SURGICAL; RECTAL NEOPLASMS;

EID: 80054903135     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03980.x     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58; 71-96.
2. Jung KW, Yim SH, Kong HJ et al. Cancer survival in Korea 1993-2002: a population-based study. J. Korean Med. Sci. 2007; 22(Suppl.); S5-S10.
3. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl Cancer Inst. 1988; 80; 21-29.
4. Quah HM, Chou JF, Gonen M et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113; 57-64.
5. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004; 351; 1731-1740.
6. Edge S, Byrd D, Compton C et al. AJCC cancer staging manual. New York: Springer-Verlag, 2010; 143-173.
7. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 2005; 23; 8688-8696.
8. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 1997; 12; 19-23.
9. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73; 2680-2686.
10. Ryan R, Gibbons D, Hyland JM et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47; 141-146.
11. Beddy D, Hyland JM, Winter DC et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann. Surg. Oncol. 2008; 15; 3471-3477.
12. Ha YH, Jeong SY, Lim SB et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann. Surg. 2010; 252; 336-340.
13. Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM III. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J. Am. Coll. Surg. 2002; 194; 584-590. discussion 590-581.
14. Quirke P, Morris E. Reporting colorectal cancer. Histopathology 2007; 50; 103-112.
15. Bateman AC, Jaynes E, Bateman AR. Rectal cancer staging post neoadjuvant therapy-how should the changes be assessed? Histopathology 2009; 54; 713-721.
16. Hamilton S, Aaltonen L. WHO Classification of tumours. Pathology and genetics. Lyon: IARC Press, 2000.
17. Greene F, Rage D, Fleming I eds. AJCC Cancer staging manual, 6th edn. New York: Springer-Verlag, 2002.
18. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 2010; 28; 92-98.
19. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod. Pathol. 2008; 21(Suppl. 2); S31-S36.
20. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361; 958-967.
21. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008; 359; 1757-1765.
22. Guillem JG, Chessin DB, Cohen AM et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann. Surg. 2005; 241; 829-836; discussion 836-828.
23. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J. Clin. Oncol. 2004; 22; 1785-1796.
24. Capirci C, Valentini V, Cionini L et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72; 99-107.
25. Huvos A ed. Bone tumors. Diagnosis, treatment and prognosis, 2nd edn. Philadelphia: Saunders, 1992.
26. Nishi M, Omory Y, Miwa K eds. Japanese Research Society for Gastric Carcinoma. Japanese classification of gastric carcinoma, 1st English edn. Tokyo: Kanehara Shuppen, 1995.
27. Losi L, Luppi G, Gavioli M et al. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int. J. Colorectal Dis. 2006; 21; 645-651.
28. Kim T, Chang H, Kim D et al. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77; 1158-1165.
29. Berger C, de Muret A, Garaud P et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37; 619-627.
30. Kaminsky-Forrett MC, Conroy T, Luporsi E et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998; 42; 935-941.
31. Gerard JP, Chapet O, Morignat E, Romestaing P, Mornex F, Acharki A. [Preoperative radiotherapy of rectal cancer The Lyons experience, 1985-1996. Prognostic study apropos of 312 patients]. Ann. Chir. 1999; 53; 1003-1010.
32. Rullier A, Laurent C, Capdepont M, Vendrely V, Bioulac-Sage P, Rullier E. Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma. Am. J. Surg. Pathol. 2010; 34; 562-568.
33. College of American Pathologists (CAP). Cancer protocols and checklist for colon and rectum: protocol for examination of specimens from patients with primary carcinoma of the colon and rectum. Northfield, IL: CAP, 2009.
34. Rullier A, Laurent C, Capdepont M et al. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am. J. Surg. Pathol. 2008; 32; 45-50.
35. Leibold T, Shia J, Ruo L et al. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J. Clin. Oncol. 2008; 26; 2106-2111.
36. Rullier A, Laurent C, Vendrely V, Le Bail B, Bioulac-Sage P, Rullier E. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am. J. Surg. Pathol. 2005; 29; 602-606.
37. Smith KD, Tan D, Das P et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann. Surg. 2010; 251; 261-264.